192 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
9 May 24
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
4:05pm
with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Mar 24
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone
8-K
EX-99.1
jofhcjz
9 Nov 23
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
6re lpxbcxjyz98v
10 Aug 23
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
bb8moiu2j03
4 May 23
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
4:10pm
8-K
shfvl
3 Apr 23
Results of Operations and Financial Condition
4:20pm
8-K
t6ibgop6e
12 Dec 22
Other Events
6:03am
8-K
EX-99.1
jk1i ilkvxvsndm38d
3 Nov 22
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results
4:17pm
8-K
skdy3h9tt27vz6o umoo
26 May 22
Other Events
5:25pm
8-K
EX-99.1
835cm
5 May 22
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
h7dtgs4 5j54
10 Mar 22
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
4:15pm
424B5
rqwyk0pwmr8g 6cez0
17 Dec 21
Prospectus supplement for primary offering
5:15pm